ࡱ> a 2jbjb "`t,^^^^^^^dLNLNLN8NNtdz O(HO"jOjOjOjOjOjO$z&z&z&z&z&z&z,G|R~Rz^jOjOjOjOjORzU^^jOjOgzUUUjO ^jO^jO$zUr^^^^^jO$zUUw0^^yO ^vLNTlx$yt}z0z yUHyU^ddd$*#dd*Drugs for Angina and Myocardial Infarction (Ischemic Heart Disease) Danielle Longo, R.Ph. PAC 16 Pharmacology II Ischemic Heart Disease (IHD) Complication that occurs secondary to coronary artery disease (atherosclerosis) 2 primary forms of IHD Angina pectoris chronic condition characterized by episodic chest discomfort that occurs during transient coronary ischemia Typical angina stable angina attacks have similar characteristics and occur under same circumstances unstable angina attacks increase in frequency and severity (often preclude MI) Variant angina (aka Prinzmetal angina) Due to acute coronary vasospasm and often occurs during rest or sleep. myocardial infarction Angina Characteristics of Angina Pain secondary to ischemia Can be sudden, severe, substernal and radiating to the left shoulder Can be induced by exercise, emotions, eating or cold temperature Rationale of treatment of angina restore balance b/w myocardial O2 supply and demand increase O2 supply determined by coronary blood flow, regional blood flow and O2 extraction vasodilators (nitrates and CCBs) used to increase total coronary flow beta blockers can improve distribution of coronary flow by reducing intraventricular pressure decrease myocardial O2 demand determined by heart rate, cardiac contractility and myocardial wall tension beta blockers and CCBs ( HR, ( BP and (contractility vasodilators reduce wall tension via their effects on ventricular volume and pressure. Differences in treating typical angina vs. variant angina typical - vasodilators and beta-blockers work to decrease O2 demand via mechanism outlined above variant vasodilators increase O2 supply by relaxing coronary smooth muscle and restoring normal coronary flow. Beta-blockers NOT effective b/c they cant counteract vasospasm Pharmacological Treatment of Angina Organic Nitrites and nitrates: MOA: release of nitric oxide ( diffusion into vascular smooth muscle cells ( formation of cyclic GMP ( venous dilation ( venous pooling ( ( preload, ( ventricular diastolic volume and ( ventricular pressure ( ( myocardial wall tension and ( myocardial O2 demand. At higher doses: arterial dilation ( ( PVR and left ventricular ejection pressure (afterload). Indications: angina, MI, CHF Contraindications: concurrent use with Viagra, Levitra, etc.; angle-closure glaucoma, head trauma or cerebral hemorrhage, severe anemia and severe hypotension (SBP < 90) ADRs: H/A, dizziness, weakness, postural hypotension, rash, tolerance and anxiety. With overdose reflex tachycardia and arrhythmias. DDI: PDE 5 inhibitors (Viagra and others) severe hypotension and death have occurred; isosorbide is CYP3A4 substrate Monitoring parameters blood pressure, heart rate Formulations Amyl nitrate (INH) (X) Rapid onset and brief DOA. Used for acute angina attacks and cyanide poisonings. Nitroglycerin (IV, PO, SL, buccal, topical, transdermal) (C) SL form (Nitroquik, Nitrostat) and buccal form (Nitrogard) - Deteriorates in sunlight, bottle only good for 30 days. Ointment form (Nitro-Bid 2% or Nitrol 2%) Patch form (NitroDur, Nitrek) available in several doses. PO form (Nitro-Time ER) must be administered QD or BID only to minimize tolerance IV form contains propylene glycol, need special tubing. Isosorbide (PO, SL) (C) dinitrate form (Isordil) available PO or SL, give TID. mononitrate form (Ismo is BID; Imdur is QD) available PO only. Longer acting metabolite of dinitrate form. Calcium Channel Blockers: (pregnancy category C) MOA bind to calcium ion channels in smooth muscle and cardiac tissue ( smooth muscle relaxation & suppression of cardiac activity ( increase O2 supply and/or decrease myocardial O2 demand. Indications HTN, angina (esp useful for variant angina); arrhythmias (diltiazem and verapamil) Contraindications vary amongst agents ADRs constipation, fatigue, headache, flushing, dizziness, hypotension, bradycardia, reflex tachycardia, edema. Immediate release forms of nifedipine and other short-acting CCBs have increased risk of MI, CHF and death due to coronary heart disease. DDI see HTN handout Monitoring Parameters BP, HR, EKG (w/ certain agents) Specific drugs used Amlodipine (Norvasc) Nifedipine (Procardia) Nicardipine (Cardene) Verapamil (Calan, Isoptin) Diltaizem (Cardizem, Tiazac) Bepridil (Vascor) Beta-Blockers: OLOL drugs; (pregnancy category C/D) MOA - ( HR, ( BP and ( contractility ( myocardial O2 demand Indications HTN, CHF, typical angina, MI, certain arrhythmias, migraine (certain agents). NOT used for variant/prinzmetal angina or acute angina attacks. Contraindications sinus bradycardia, heart block, cardiogenic shock. Non-selective agents are contraindicated in COPD, asthma, DM. ADRs fatigue, insomnia, dizziness, bradycardia, CHF, edema, hypotension, mental depression, hypercholesterolemia, sexual dysfunction DDIs Verapamil (greatest potential for ( contractility and ( CO, other CCBs safer to combine), see HTN handout for other DDIs. Monitoring Parameters BP, HR Specific drugs used: ((1 specific and non-ISA preferred) Propranolol (Inderal) Nadolol (Corgard) Metoprolol (Lopressor) - (1 specific Atenolol (Tenormin) - (1 specific Antiplatelet drugs Aspirin MOA inhibits synthesis of prostacyclin and thromboxane A2 ( prevent platelet aggregation ( ( thrombosis. Indications several. For angina - primarily used to prevent MI in patients with unstable angina. Other agents Clopidogrel (Plavix) Warfarin (Coumadin) New Drug Ranolazine (Ranexa) (C) MOA sodium current inhibitor. Indications Used for chronic stable angina in combination with CCB, beta-blockers or nitrates. Contraindications pre-existing QT prolongation, uncorrected hypokalemia, hepatic failure, if taking drugs that prolong QT interval or drugs that are potent CYP3a4 inhibitors. Precautions - can prolong QT interval and induce torsades de pointes ADRs dizziness, headache, constipation. Less effects on HR and BP than other classes. Prolongs QT interval DDIs CYP450 substrate Overall Management of Angina Modification of cardiac risk factors Goals of treatment Relieve acute symptoms Prevent ischemic attacks Reduce risk of MI and other cardiovascular problems Consider Type and severity of angina Occasional episode - Predictable episodes upon exertion - Frequent episodes requiring regular SL NTG Angioplasty, stents or bypass may be necessary Consideration of Concomitant disease states Asthma CCB & nitrate most preferred, beta-blocker least preferred DM CCB & nitrate most preferred, beta-blocker least preferred Heart failure nitrate most preferred, non-DHP CCB least preferred HTN beta-blocker & CCB most preferred, nitrate least preferred PUD beta-blocker & nitrate most preferred, CCB least preferred Other factors to consider Beta-blockers only anti-angina drugs shown to reduce incidence of ventricular arrhythmias that cause sudden death in pts with MI. Cardioprotective effect so many consider them drug of choice for angina unless otherwise contraindicated Patients w/ unstable angina with high risk of MI should receive aspirin CCBs less preferred than beta-blockers for unstable angina b/c DHP cause reflex tachycarida and verapamil & diltiazem reduce contractility For variant angina beta-blockers NOT effective, use CCB except for bepridil and nicardipine Pharmacological Management of Acute MI Goals of Therapy limit infarct size reperfuse obstructed coronary arteries reduce morbidity and mortality prevent post-MI complications Aspirin antiplatelet agent. Dose: 162 - 325mg STAT, then 81-325mg QD. Use for all MI patients unless contraindicated. Start ASAP, continue indefinitely reduces morbidity and mortality associated with MI IV Nitroglycerin Recommended for the first 24 to 48 hours in patients with acute MI NTG alleviates ischemic myocardial pain Analgesics Intravenous morphine - 2 to 4 mg every 5 minutes, with some patients requiring as much as 25 to 30 mg before pain relief is adequate Pain control also includes Beta-blockers Recommended to start IV dose ASAP and continue post MI with PO doses unless contraindicated Reduction in morbidity and mortality - immediate beta-blocker therapy appears to reduce (1) the magnitude of infarction and incidence of associated complications in subjects not receiving concomitant thrombolytic therapy and (2) the rate of reinfarction in patients receiving thrombolytic therapy. ACE Inhibitors Recommended for all post-MI patients with substantial left ventricular dysfunction and/or clinical CHF Calcium Channel blockers Controversial in MI does NOT affect morbidity and mortality. May be given to pts intolerant to beta-blockers Diltiazem ay be useful in pts w/ non-Q-wave MI without LV dysfunction Anticoagulants Unfractionated heparin Low molecular weight heparins Enoxaparin and Dalteparin are approved for non-Q-wave MI Thrombolytics/Fibrinolytics Fibrinolytics are the preferred therapeutic approach to achieving rapid thrombolysis. Fibrinolytic therapy provides a survival benefit for patients with acute MI, based on large, well-controlled clinical trials MOA plasminogen activators. Dissolve existing clots Contraindications: Absolute Contraindications of Fibrinolytics in patients w/ MIRelative Contraindications of Fibrinolytics in patients w/ MI- Previous hemorrhagic stroke - Other strokes or CVA within 1 year - Intracranial neoplasm - Suspected aortic dissection - Severe uncontrolled HTN (> 180/110) - Recent trauma, head trauma or major surgery - Recent internal bleeding - Pregnancy - Active peptic ulcer - History of chronic severe HTN  Examples: Streptokinase 1.5 million units over 30-60 minutes Alteplase (TPA) 100 mg over 90 minutes total Reteplase (Retavase) 10 units x 2 doses over 30 minutes total Anistreplase (Eminase) 30 mg over 5 minutes total Tenecteplase (TNKase) - 30-50 mg (based on pt weight) over 5 seconds Case Study Jack Smith is a 52 year old male with a history of mild stable angina, asthma and PUD. He comes to your office c/o increased frequency of angina episodes, which have required increased use of his sublingual Nitroglycerin. Current medications include; NTG 0.4mg SL tablets PRN chest pain as directed Zantac 150mg PO BID Proventil inhaler - 2 puffs Q6H PRN Salmeterol inhaler - 2 puffs Q12H Flovent inhaler 220mcg/puff 2 puffs Q12H What other questions might you ask this patient You want to add long-term prophylactic therapy. What would be the best class of drugs for this patient? This patient has a history of non-compliance with medications. What would be the best dosage form of the medication you chose to improve compliance in this patient? What information should you include during counseling of this patient? Write a prescription for the drug selected. ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction  INCLUDEPICTURE "http://www.acc.org/clinical/guidelines/nov96/1999/jac1716t03.gif" \* MERGEFORMATINET   INCLUDEPICTURE "http://www.acc.org/clinical/guidelines/nov96/1999/ja09965120t2.l.gif" \* MERGEFORMATINET  Reference: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction (www.acc.org/clinical/guidelines/nov96/1999/index.html) PAGE  PAGE 2 tvD - . e f k l t u   W X 0 T U t  ,-CDFGders jh`$OJQJh`$5OJQJ jh`$OJQJh`$H*OJQJh`$h`$>*OJQJh`$h`$OJQJh`$5>*CJh`$h`$5CJOJQJh`$OJQJ h`$CJ =,E[tuvx5\ & Fgd`$gd`$ & F & F  & F  & F 8 & F & Fgd`$ & F$a$t22C D :  ^  & F & F & F & Fdhgd`$ & Fdhgd`$dhgd`$ & Fdh & F^   N    } ~ / 0 T U t }~gd`$ & F & F ^  ^  & Fgd`$ & Fgd`$dhgd`$ & FdhKL:Ivw|}uv !掆h`$h`$>* h`$h`$h`$5>*CJ jbh`$OJQJ jh`$OJQJh`$h`$5OJQJh`$H*OJQJ jh`$OJQJh`$>*OJQJh`$5OJQJh`$OJQJ jh`$h`$ jh`$43456$[\]?@Agd`$ & F & F & FA~,e$LH^ & F & F ^  & F ^  & F '9:pJKLMY34J\ & F & F & F8^8 & F.o f /0123F & F & F & Fgd`$ & Fgd`$ & Fgd`$gd`$ & F & F #A#R#_**5-A-0111j1k1l1m1n1o1111111t2u2{2|2}2222222222ŹŹŌ|||q|h`$0JmHnHu h`$0Jjh`$0JUh`$B*OJQJphjjOh`$OJQJUh`$OJQJy(jh`$OJQJUjh`$OJQJUh`$OJQJh`$h`$5OJQJ h`$5CJh`$h`$OJQJh`$>*OJQJh`$h`$OJQJ'F]v ;<k _ !.""####8^8gd`$ & F & F & Fgd`$#A#R#e######$d$$$$%%%%%#%%%%%% X & F X & F X  & F & F & F%3&]'l'''+([((((")#)$)A))*K*^*_*** X $Ifgd`$ & F X gd`$ X gd`$ & F X & F X ***+7+U+V+|+++++,,zzzzzzzzzzzz X $Ifgd`$xkd$$Ifl0,"LL t064 l4a , , ,,I,x,,,2-3-4-~uiiiii~~ & F X gd`$ & F X  X gd`$xkdL$$Ifl0,"LL t064 l4a 4-5-A- .!.>.?.o......%/&/'///7080000001 & F ! X ^11t2}2~2222222h]h&`#$@&[$\$ 1h/ =!"#$%J$$If!vh5L5L#vL:Vl t65LJ$$If!vh5L5L#vL:Vl t65LNDd^Z   S 6Ajac1716t03b$N,4h'&%HffNnM,4h'&%HffPNG  IHDRv +50PLTE)))999BBBRRRkkksssfwbKGDH cmPPJCmp0712OmMMIDATx /~{KzI5}n1_t "_hXܘF6qaLefQ֙>˻zf hTWݺUSn{ `@C 7!ulT̂s}2ec]vY8ѕWgK5n u"PqljUӟ H=pd?|F,;d(4 tXNI IMhO+8Իޒm'&'I琔&Spo.huqC\'#1۳t*8!`%|O3A9`yQ6AbM4Nz-$,ELi)(՗ã7 )sqTL)}_Hwi[`O:yaf_6 b4 &yaaJK_Ab&1L:_%ˈ%a"Nݳ 9W2S% C$'l D[VmBapH |hdOƎ*u 7RLw n_B0G泌HOP 0ɍjacw;}I`v:;oRAQ1[ },N,QK kiƽrJЕ; U7ރV𙐓5:Bo)7 OQ rKVO,B]s%״#ە{q:r{|(M80MwUP(wz" L]5ׄ`+w@AYxk'WeȤ-3Ƚ4@5:Z`(IJʇ3Dm{Q;!I@%b}}^7I:PN!QaEB4zR@| @<vjGnώLpv_ܓY;FCˮoV?ឲ˪[̇fs; qU*r>U(}Ͼk.jr6Re[T}ʌvK% X29 V`1+a#u!zweC荈) *$)1R72Z͡.:6jpMdB3 J'$,4Mߣ6LѸӚo.uAq  lV96( u -ZjӡVs4|TށoM[`I `pT AUT؋:W_W[j@UmEmUMUemMMMeRE#.).saш.3:sEg^uWuCꬫ.)Ec[/dSflcG;b̘̤3_S\\<ѭ1c.-.QUVp+ [ _?,_f(w؝)_4MT5|\ '!!dH@1]8`e\YCUВW)1p Ε;Ll w(p4ǽ:R[Oel-a''M" ƇKl_ҁÉm"7greվ&ڝU=2mn5w>7XbxTè4sG;{d*ikbX,5:WsjAKrO~^iww G:{*6\ݬxܰr{ io6QlEjwj'; ȎbSmժjv=nEP>e~HX]yo v7Úek30W_UrxƔ^2/C\$/h0ٮI3z_nexX:Y~]JylW[gIǭ)V1 C<ԎRWo[U({>'LrF,{zjN[$.ԶJI]H_8~UlS P y5]H21T-zN%bdP-;It̜x!b&d$b{D^*c/\C6:EoS+ ֝«J%[c Ґb%¡<1Y+6keQ >З~2mVH" ZeV2[t+Fشy'앰DAf^^@aO |bu\k&Nc>Ioxy4_"FimVz~ 5dk%bs66J3 4kiuQ EYu21X R[:z*g1XTN6*WY/۪ ։6:nPdfɹJ(lkPjA (XJF]S';*ԳT*VM~6.ͷ%"6V*&)2]Txn <7f1x-z>.b菦V֨"qsmжL>9'#  |\=Gۣ(w*[H ]k.Ha!\{BiB J!1Tq6e6lxQ>aPӮ{;Nrgڠ2m۪uoq/&0 Vѥ)jjuMI:&,'0=rټ 5߼!pZtzWr ՋMw#۬[a1H1-(l< /eBm%o@e&]N?H&pADwjzOk!-XXQv]ےfhgpX 0C5Q`F6Ϝ̙_dK8m bp;piǕ{Ig+Φ>j@bL a.eYnD8+8 0O1Ar1gbR!ϸߞ-X'&H0s5oƖ3PBlʺɕ$b+' 0}G쎥<"3-wo1Oa>aVl6`*!͒VlRbvȱpHVt{] ;US8li] f:alPoޑxIdqj˘pHqbs,巻MXf0j7s:S q$m9ܳ9 '"D:8u*!aI\Uu#Fh¬ X>ަkC C⎚YP5Tu0B҂Z[sڈ&NNxLI&mb,fO.&nL $ 먞6t eKC2[CY e ޘJ쌀E>.r Vhud"Na$[LJeĹ> %X]n%Wt k|丿%#4C,ʝ{ ] sQ4ڪ1?#/A\g坟:!u򔻊Άx;rsb]wOޏ㞑5F]2{~-ģv#=+DY0h|"Dw2"+mbH{ݒ fqV.ZBE qj! 0)D N!{l)-fC[& Ѫ@+P*c)?CS>mbA= Ꮙ{&>SJ}-l iA0au&LV )T}j)eJ _ʑIYZ;&TC ԑtX*XtрVJ 63#T]:? y`}2:ԕn|1/@rv9OM[|7vt(]CQGXcwC^Pp{YZky2[OuL/lu&^هU<*FZu 0D>̀V{pw!ǝ"qurvt ]s*t4b|+"?gv)f];A>QyA7Gw٪#0EFYjq?,X@r]J !Z9є\eqTI5Ҕ{f2oD '}亚mê%DϓQŌƉ >[I`prB*B,6 jSO'VF5c~8N42 .\'U lXCx:zI~t!m7GPNϩdcX[5z5Jʨ.M!:iV d@胵5C!=5sZbgۤ0$,t$L Wӌ0\7M-4)aNتk7 S-o5w:v#N_('O#snoO! 8OenGtF k{{8 olWH??1[fmZ3K{l }e?M0X}΁p<'K |i߫Su~qOf%(c̦z@>_JQe[褥1`3L@A))(]r/df+`.JH!1Ӻ3iQW@q_ϜvQ!MB1H|ew29KE[]fmE -v:}~-vLǸdY=íP֗:,:~%vj!v6l&UE#:?&X|0:z|2cE~!ZAGHc9=rvYfP:=Z} Ȕi]އv=`F#=z碃[Z>=礘숥e>};y8FNd42̡v߀T Tvg(| Ŧt:ICU,7 9Nϋ*;`c0ss)Dɦԛk53Hzb sȺYAyWʪQ'Ii6>n|_x@i?2]OF1-]_+ >"խ_+nbn𷵑Фex// $frɀ{twfQʆQ;)ɰj]*q gR&G~#≀%nWgP$ x.,G~+y+2b?b3̕}f'iI_L!ht7(!N»5LZ{e/*$L!TTlӹE!CV I3N>"pǀ2L$nׄϻ>F9 L9N;/I<$7"u_"1<#4`z}/'+ ѱ(j{ظ r"SltegK$Lyf>#}`APrQLgE^b';X^+ +Tn }QƝ{p{Ļ#H*p2S-orYM2E[zg@c*{FrShYC \gcIH%|ӌT) 4\kr_:9Cz~e12D{梄u 8ɋZƤM+b'l^tHñҟ=sP;墀_*v=cfʭt {`*$0*i}Ɇ``(R+w`+fu6[{6fl;Բ:SةX5xƁPȶbUPUN:焪.*_=z:ֽկIy{KIm$u:u~I (-4Q|_GBWMfmlvlPum1Z^xQ&lW6 n[NYPgk ;զJ5Ä{ڴbnc͓>'tr,Yc9ɤ* #U;$gYy{xc : 17Q#CR&Sn2fT%L"@E:po] &T}TQN*ιè,R>!Huk|~-GI6"lY *VKGA~!c1}}3u&r)YsZ4VxFgxfvV{0UOM%8l$˔ Y)D [}k2!jN{0T.sB ۬" nvSn5u:#8{o}5= HUL{hEպZH0b1 P OowIvKx-wS:5ڹφC,9@:mqUǎ_ޛk1'ߕ]E?MojuPܛr˳(뾍f׋Y Ze; KZ=jxJ.M>ɐ7 nJl9.RҘQUDC/웺e3f1:ST#7Ƹ,8ѽM3fpfZ3Od:QI96 i,2Q:ދ.wZ{b;I+n8LQ厲DƐmRx&=,ܱ{_] }3 oR6TL sazAgPIAĤɽMCD ^&܃"@ʷ=xl+QhSnzgAz%,#LLjs Ec?`y>B$$~`i}AK?5ϫC5:,?Xs'x(]`\c qhMbŏ2,YY4c:C%s֒j6=J{A n*xwʈ$v2!&ۦxF([h˷˱MntkXͨjةI 6rUiJUi۝.FXH~Kpl¥KfˆrOUcC<'l?PoHÅ؁}NhGY]Z)g擄 BG^bvW4'=$ork{@v474)$ )2*\Ώ cRHiU&&|80^XpA/$GpB?\K*MlWQR b8rV q/.D6Z;Qrhk3h>(-1,NXw'6zX. 3cmT?MޤQ9TRm?-j= ڣQcyv/#kM/f `΁?\Lla9wdmbtL ^|y*p`uLڃ`)+nԸZu[bvU:w5zxgk7@,qӆs|]{f!'g~Ejr\ܜK væ+ ht}-3[T6RE?H;}HUu}Fi-% e!pac! C%B:]~g܌ ݤIaX }|Vە0(N- O갢ddrw񻌾hYo&K#)f!rdF'@ŀ%1?b3%|hKB+X<Pp~ ƼTDdFDJ@{>a=&닆_CbaR~L lݧRK<3ȼH\D T6=l!z ?cx+llVYF Ao7~㺤/J;UwcÈ-)=T@Al"V&)@&fnJ<ƾʇ5ƳR/pfc㮍b6A?zw F͙7!g}h|0# k=;zr`A&'g' !2H*{weWlr|hVYI A\wG! ;}}钜F6B4_ZۦD D]DNأf? gⴞQ3$VxZن--OߖBBpw㙵>"PExw$v%nV[ۄI-YjSRDO% @3jm%2-=5ꟴW ZiGj oک| {U8ݵ_uѕo [ K!,X,Y&m X`pr}k nч +}}&uԟL.J{B|?`=MRln]=]L;ȜΣ|ekƞ9}٣XTC˽SOuA/+&5o_KfF$ Ef_2AkJ*9ڝ帺jdS s-[zEzOJjԝmb8uvX l_.3'F\bH"wƪ䷠(_ޓF>~Fƒ~$- @jn䤒%@ $JZO84lKv e(3G^'ׁ ioZfްL9ځ}4 2^ȺЧ#bBCׯ?T#^@Vn`DOx7} o%ܺooUhla!'wi$tC[ŇҬ3M>G4D ]ce 72J^5QÛ5CY^+#h'4ut/b&SLPn- ḆC6d"V!Vkvyd=4zޒLn&%߂oW\NkcjIڗEQOum 幵x[4!B뜻bÎJ6 fQR5b#iJ`#ɮ@ Ylu`t h^9)t]{r.9U&"݃LWm)~~ND]״|p7@ վ.ĉwvG7r(wt>f>;_~dv5bVs{:PvOV+G6ۼ[n頯$%iWgŧ~$E.3\L4xN*_*vb'b !OfR熚xHS#$8tـ#IgQ).l0f*C `pqYI5_dZ 3˩X]* ia Ʃ^FT|Voeag+s,=HdvXfnYt @6$g9 -&vTB_ӿ-UZ~e7Ɋt\j ]-nrOE(cL.HbKTU!3+Nx9{3Z2>TP׵xkciNxͷL&OF|Bu)IT=CAq:&"v}I &x7P tj3QtcN|T<<ą$fh#&N > "if{g1ʽ$}LMf8Y2 ` `z?iQ-zf߽A|/FT*)SjA!e0AoQVDR2 ??!帓YM =lLd cs ̇O\^'bTLWB0q0qO62ǔL\\N@ 5l촂Q$"Vle68Gϥč)ws5D_,I0ON}8k9f˳j0hG!޿a~b#}`]t-989ts|gl+FM3M3nupbxU ;˹ppau˝oٔe%SŠzXR:3wEҺnDYh_ER}nKO~;LB,_gkDF3Fd:'cęHp|rmpcH,[x<0~h1g~.DpR*6z;[ۘEv/m$1̄҂ً6 LP|j¥^c*eo fkV#Ddr&"h٫D,<|B餘4$i֓Pk, !!H=diqD֑HnclA֕(g ﺏ>(T&v K(\8rb`C-ń}Vp(zषi&OLIѷ$$WyN,h3f83ָY@-refPuv*:=6 m`}H6얙f; a2 .Q1k0h}Z,$X&X-׺gBnƸG(bZpr\b_RǃD՘ܙSz1gav-ldHyƴ܍>{-2bq'6}ORw &H%Y$! ׄy-MeoƜw"T}+degM̐@:|$LQyg$J^Ai:u[C[ )o)`;okK%-Ҩ. )NK_o;JRS Só?vg@J8Z Dearn-<᳘D+;S٥^g7σIVaO-f*cO'|Ø 0%]W ҝkvn1C98|fӓ:m*ReK3w5n1]ǖ^(BzwƬ 3a [ݦcJ#l:8 \ПԻn)7j׼S]53i>:f1_.zN7kɎ0V}C:ߛ\oz?GA%mW$lw b7a@ɤtR$ S.q[’|트'B XX$C*) !{Gze|E]Q녮Xs;t$F>麨>1:xt xd} Gosp<F)`7:䣵]k b?jÈNv;:3&6+٦w3 Dӝ5V4t -]:`weڞ oO/'2h^*oL~cQ7fO&_Wk7]ȡb-b|VavCn%."ʢp+dyB  I(Zw2T{rb5s{l sGBc l"¸O[<1a]Dd2~ͦΓ*BfC$slH'ElT ^n@l!mAa=p(1q+&@|7owX۞%/P'|UQ{f{];՞D733.D_g;) s1̮ծYvIH&noz>8ToylxiH*  0?!F^L9pF%i&?m?åץɳIqpE",Y2򀆏vT,\.YZ`.Y$4g>Hv 3qV{flFDGqX@a<1H CKgI,7Zzt'sBٺQI|me{9ʌ,aL&\ *J bRrpǜ[$$\Ƃp&8dɗ:k?w/k7Qinʂe B)>L&ѕ{r/L AzyIM۷; Q@-Z$\mG1DY)u>DMX 2J40 k8,[Ŧ #meǛ?_3_~ 7 ʢɴnga@gNZOvwCuVZpMO88,JVY<*8a5 e}C텪ڪWUYCrXtݲK.[l;K.x睅,XW,xfs2w}>Y̧f͚5uԙSuXEg]}ш3G).*1ꋋƜUtՈ]uYEW9梋Y-ExDEW_]t.**bEW]|W_|uх zUgpC2 ]xСg13~tC辳κ_u˙QT\Z5uܧ}Ђw… ,]tܻҡ"y` U3Ԇn;{o_ZjU'^kX'2P6g >4{YJ'OjWPQnكd{N-'*aSsnvJrQYTr{>fW57zH Fї\:M b Eo"Bw;;ʽï~@vo 46mM"WQrVM+Re.YP5#B{ίK4 [`iO)6Xi#V d4H['ƈ'ջ;v9Rp`?m0-h˝c3/Ǒi!/ܯ8C>ܲ6)-ƿzwo0*!ІoL(kXI%_DA|x58O-];ؙ2.\R"Wp>>eE;A~h[{t<tt5{0( <6mG#h=Ch8p%jx^hݦD {\(`h I@nmTK պ+}3@-HlvQؤV4A0=Jx^l6J;vYg5i pUlix ~; 50(.dW;5Kc,SJ#0 SnKir%;[=Tp-864z yFKS<^g-ۑTQ ̉`? ͻ"rў, ?12S`q#8MĈK,HFeIdEB`>$^ MxcJ( *? "Az]FRZ|$1v/s笛Ԥ`PJ'\/Ax๮MQH>ZfṾ)5Dj#VwgSg23˄} gGHdIAl%Jql iy89LDh{+n'=.Eә"BOyq?Z C/~.>WG( :rw0;.Dгqg{XaD KfL'=oUc9ն EAb%vaFeex3k{[X(H:1G[=1wfmFS&iqz3Mm)^(fJCg`dyg&*JV[\VN6&9WvQPFB0 BJZo4Y>r5NIm: nlӪ0jvVmvu,oe%XJݞS?[dsڇ@vƫ0wG0a::Qն#,vG!ӹvX}PLAھ$S\Ŏ0fN͝?]Ab(krO=rCLKt>Z&>%̉!|>z_q;47:tޜT]iO@?FRm?+ra6MQ/TmOdzGpan[<,Xhv=lrZqͼU-HU+[.ӰY"FRU5FLYmcSGg6M~jyGOOz3HR1,g9'úL.l Aʕ5=mGBk--\4l%6ߎ:U? > Ḣqb ^|;r1zISe&%Fz\!%q )&跚X',IZ޲fcJh & 5]=O1>_cݹtDşy7t9f\8Źtף߱CBAVȼҌTҙn[/l1*97O#zmn@sG*̱2MaFb{@9!O {[]=Li =DƧ^׼ce]S øch˽\ h59[̜.uuաY7_Hu+elbm{^'PA5Iy,$dԓzW203ח Pv~ؚ dtQ)⫷0&iRJ3'; <"Tm`U+-SDwu2;8Mn|_ְ(@'w3mS#ȔD:GoY29cdW%ofx$iq#; BFbʼnfi(.S`1(Q(Y:;EltvZO!{,-mr?r"ܠ(---޵lp%D,^,s3TB q58bOg^4(.>7o~H(nwyY_] Ke*k2?TGe?mPzN:VU(wydT9s}Uꩶ9k%]ߎݤnZgըB8 `BM`MЊֲn/:MK\A;:<ˉ]pYmEanǍCGˍdB 5Q۾EmKK!+O5]*>* n`ϗ0~K!DD %H0M'E8VBQ8y'>c>קb0x?m9+IPP7~0N%p)B{Ԥ1Jm ! ${gR&J)/ xXH1TS$)wlGfY$0jkjĆbEDɡ) Hj~ C)?J2qpUv;!"g2I+w^~\)~\6 /7+<"1 ; >6ڹNϰkSI;&m,&1Bmw-qgQf$l̏_l&!-%\A-]҉d@I ,}!>G˙0@ n{y/ ӇO=iRipMs Rr `Ep7qIENDB` Dd: @ ^  S :Aja09965120t2bY+?^Nb$?5On-+?^Nb$?PNG  IHDR&bsBIT|.wPLTE000PPPnnn&J cmPPJCmp0712OmIDATx<QlUUQzAbղme p7Am0o>cH~u) ZLZo3v.ٝ@c^77WCfbrbTbWe8Y>N`[Y,T4k|C"IO9~wye2ą%yƜga,ff-Ʉޗ@=J{\ $r1&-#ܒ #q-'0K8&'Ief6> Oz4SͤZ/+uIvIp^+I@E]npjӚfyp<Ǎj9:LҨ3dB[G||A3廩 vdKƎ(G5pIz{{f|}Dε>Lt}NUUKdY/|:0f}="+>ffk8=-촘w[7bUɵ~\ɵ@6NR0A̴X׈aY3#c{?2Wa<5X%O<0$f徆Iޅ+sfq"(-+xfZnoFt85o9#,Jw}NH=w␉p9Zq՞ [NwS(?mM*3 zvGp=s)Ep0(:sΙwrf-bm>-v.\4čF"7U0Qp".쇑f/ٿPKP v3:y᎕ Q|EG+>]$ "cbf>qA 6Xy{Mceb&qBV5;m1&QV' D̜\ɚSs"r!367Έ~gg9;;Qwi&K&z?I`Hzp2qz~Z??#j!gY0^V֓҃A]gC Qr2?j&(܏w{oǯs3t۳%'T=j+vmWlƺn[wtQQ O{֗:0[\ɵ(rwwo9 <m3!g u$ Hxs& 0O6`/"|T7^~8WlnLN]z֤zD]JŤL|qYe5 ¾@9lgh碋mB@D%IL#< s[k;=yBճqg-NSeč4D xҟ]tbRX0ԖQޟs; J?tjꂱ1&<֧ 2=;6L6Q&+w+֥3!Huj}0O2CƾıҼg͊nT ,<9;UkHa%ޠ4Y{%!z A-ǘBkL{&lk| ?Ÿ3m4{yx` vr)HA1WV@ 2uc^Vy,|Mxp~2ۦ$*ء nAo)GLEwTm߲+m̩l684IPŵME+'g&},'1yۅ1akZ_/zn4z fU-"` G&*L7qBO#i2Q/:|m \3&Ďn]UƊ 6{!݉1g "Qek[ebvZ;, izw*_7gzih^ڥe"-:Xnʑl=) gUк4(R;ʋJi=cTL/ -#aY-X=l3KSЀ‡0/hF)BGCiҷkǎ_IDO·csm{>? ߎ7Ijg}H*^ֻ-ʞź'ZMI nFQ.m8_AV͌7b~yM619'RE }~v,3.e6-b@Jq,Le#2RNgLL uXԞ aGi4zғ6}Ȏscz_$Xc_^4AX^h&3coW]h56!*mU|']*ӶyόLܑR>o"wvVPBnj{ ]Wb]jDAѨ:ԮZH`kƹ* sن~aBMt6 ~0*=W #_iZۢPk KXXš&PE/= .CFdPh7{L5v mj$Mj=lՖ鎉loZ>o;ZLZIQ j$M޼{M[LX;W3rɚN6J0#n6Kqk§i(N N-*%7 n|*W3;#![2H9H3`"هPm-^hKD7"dFի>SR/!>]{?މ=g.q冰N9@F#4R&끂C6mH~#ks2^Ji;],<bd_Ikm equ$=B < 9v?XJ9K<38_s2^ˋC+1]ZFXUT#. IR1HxTbnGEs=3oX9:*Z`2R¬)A!q}R zp/eYUszQ h?5–yk}Pgm6=^^j;u&t"j MG&ᵧO">6s_!aĦɯ)zaJb󲛆]M5\*=C5sԨ2%9|Б%H -޵I[%E x! 0eaiY T|1 GIC.eRQʀCR&,@-54_#ZSJ0tdV![cg-t{+蓪شP9 fզAYsS͎#2f d2|zZdgy?ÌV%nY(rw E&q7 N۱POɏy>OߴwHlUHr=ױ#.D WU9=Ia#"a!ԭ$ü mI:em_b;Y䰏 \I_?=&qѤL^ .K"L`$Nqácg~?>19v {&l(;++tL\II؁FU[yIAZ $H%=Ch#7^ pVSܼ*R9{+HUzbɕ\{.Qؔc4q3¹+$L^{Jbu\sLEMJzT3#9Wk4Ѯ#tٕqx;P,zcu_-~"8!-˷Oed,1ڱ;>)h [کIj} /)/iȯ(<.`+U2lx!t`y!"O>IФL%a4}Iu@(Q[ɦ xJeWy 7G"v ?CDπ<2s r]ICjkP?Ty _ ˩;8ve!DhT]+adQ m2&Դ164T`@0,Xhkhˁ̬[4Bkgw Od~ڷ|ntYVSg#df:_7qSNέwŘ_cV:ouN0%9I*5} JV7KYxa<)&IA ϊRĉ@Kց1to3 JW-˲pba>]HG./ku\ЧGj] ~xssdl㳕 sFUjvkCL~"qBG7eHV5z*tn&Ƀj\F@6){7$Y۾N,U50mBFyxmlSѣpJ" -UtLִ(b#/ yV"2A{ Ԥv8TU$1-USj YQU}R/+UVQWxu[YaLP~Bu8b[k~v٥LlF[~qAes0!=˗Ӧ?iJ֮K+ W|eiqgf=ԧ gl+Weܬ,pl|YMu 6t=2vx?[7=lLҴ~ebm{UmkW]CFpW;nӞ J_zbwSkZFZ/ZVvUڬ/$$q/G[$ 6 )ͻ[CW" ؀lm #-OZu =)8lc.zJٮgjhSu]fLޘkZȚ3 KkW*EZ=s$@YUҬd™I[ɘFˉ!hI(p6fˆw\VNܒNa}HH3(k(fNyPE8yA7l܆(!iツ6NĻJ% TdVcB|lZPt <"BuVn97Hw斝I`e⢖qQqTR0#yX'ns[]X`z՛(lY6S6A]]1$]SꪵK ރІeRFrG9Lt/A|MG~K2e 5{.x> I0K $WRHӹ;}Gv”=6!!fʯ7V<]g-ijّN;!J!Ҏnu:cbj3$r mzZK]6g<-u2Ԝt ԗ9t&SqVVOx`^3 Gz}C]QRKؾSC8,U 8J\NX jr$3RgܯUa,U<߲i )q4)J&73uyG#5f^9櫈M G I.n=B$'|ɵ39q6uenLNfJc7^M<.3n70\.kEQ)Y* A.i%;ζUҦ^'Pp-PQ!6jd6Λ+:E__{Z ~k>(o y)n%C lv@A0ִL,_dmOo/[T6OJ,֬¼cB `r4g"ϘPWy}v%65QiI9 K܄1F]uR& +:ϮiHq= ƞqǏC[/hyF~M[g$_ܸgc.jƄ%Qh&BQp,gHVM ٦wiVi* g .&iSmkxl?O`nKD'ݹ!~1y ~lG3Nw9'k\wZߒ~!J=\܉N~$;|[͘Iq^usF lNkTZ߿mTsKLZL Oĩ}bH;)bs$듎"0YTNfraI ,j\҅k$:A;E(Dz֮89]4F  \Fn=k~7wzI7R&K&JaZZ `J\8_'vןbU9W9髳iLTX[yae 6=i 5LxaI0hd8[IBU嫳iLd[E8(Ԕf3m3[ + N!,"PRnYjZPd}sb*OJQJ@@@ Heading 5$@& >*OJQJDA@D Default Paragraph FontZi@Z  Table Normal :V 4 l4a _H(k@(No List X^@X Normal (Web)dd[$\$B* OJPJQJphZ8>@8 Title$a$ 5OJQJLC@L Body Text Indent ^OJQJTR@"T Body Text Indent 2 ^ 5OJQJ6U@16 Hyperlink >*B*phZ4 @B4 Footer  !.)@Q. Page NumberFV@aF FollowedHyperlink >*B* ph4@r4 Header  !j@j `$ Table Grid7:V0, ` !z!z!z!z!z!z!z z! z _3'*,^A,E[tuvx5\CD:N}~/0TUt}~ 3 4 5 6  $ [ \ ]     ? @ A ~     , e $LH^ '9:pJKLMY34J\.o f /0123F]v ;<k_.ARed#3 ]!l!!!+"["""""###$#A##$K$^$_$$$$$%7%U%V%|%%%%%&& & &&I&x&&&2'3'4'5'A' (!(>(?(o((((((%)&)')))7*8******++t,},~,,,,,,000000 0 0v8 0v 0 000 0x 0x 0 0500 00 0 0 00 00 00 0 0 000 0 0 0000 000 0 0 0000 000 00 00 00008 0000 0UUU0UU0UU0UU0UU0UU 0UUU 0UUU 0UUU0UU0UU0UU 0UUU 0UUU0UU0UU 0UUU 0 UU 0 UU 0 UU0UU0UU 0 UU 0] UU0UU0UU0UU 0] UU0UU0UU 0] UU0UU0UU0UU0UU 0] UU0UU 0] UU0UU0UU 0 UU 0 UU 0 UU0UU 00UU 0 UU 0 UU 0 UU 0 UU 0 UU 0 UU0UU0UU 0 UU 0UU 0UU 0UU 0UU 0UU 0UU0UU 00UU 0:UU 0:UU0UU0UU0UU 0:UU 0:UU 0:UU 0:UU 0:UU0UU 0UU 0UU 0UU 0UU0UU0UU 00 0إ 0إ 0إ 0إ 0إ 0إ0إ0إH 0إH 0إ 0 0 0 0 000 0 00000 0 0 0 0 0 000 00 00 0 0 0k 0k 0k 0k 0k 0 0 0 0 0000 0 0 0AAA 0AAA 0AAA 0AAA 0AA 0AA 0AA 0AA 0AA 0AA 0AA 0AA0AA0AA0AA0AA 0AA 0AA 0AA0AA0AA 0AA 0AA 0AA 0AA 0]!AA 0AA 0!AA 0!AA 0!AA 0AA 0"AA 0"AA0AA0AA 0AA 0$#A 0$#AA઀ 0$#AA 0$#AAȀ0AA`0AAৠ@0AAˠ@0AAˠ@0AA@0AA@0AA0AAπ@0AA0AAπ0AAπ0AAπ0AAπ0AAπ0AAπ@0AA@à@0AA0AAເ 0$#AAȀ 0 &AA઀ 0 &AA઀ 0 &AAȀ 0 &AA઀ 0 &AA`0AA0AAˀ0AA 005'r&05'r&05'r&05'r&05'r&05'r&05'r&05'r&05'r&05'r& 05'r&05'r&05'r& 05'5'05'r& 05'r&05'r& 05'r&05'r&05'r& 05'r&05'ˀ(05'ˀ0*ˀ(@05'0000@0pˀ00,E[tuvx5\CD:N}~/0TUt}~ 3 4 5 6  $ [ \ ]     ? @ A ~     , e $LH^ '9:pJKLMY34J\.o f /0123F]v ;<k_.ARed#3 ]!l!!!+"["""""###$#A##$K$^$_$$$$$%7%U%V%|%%%%%&& & &&I&x&&&2'3'4'5'A' (!(>(?(o((((((%)&)')))7*8******++,0π0π0π0π0π0π 0π 0vπ8 0vπ 0π 0π0π0π 0xπ 0xπ 0π 05π0π0π 0π0π 0π 0π 0π0π 0π0π 0π0π 0π 0π 0π0π0π 0π 0π 0π0π0π0π 0π0π0π 0π 0π 0π0π0π0π 0π0π0π 0π0π 0π0π 0π000π8 0000π 0UUUπ0UUπ0UUπ0UUπ0UUπ0UUπ 0UUUπ 0UUUπ 0UUUπ0UUπ0UUπ0UUπ 0UUUπ 0UUUπ0UUπ0UUπ 0UUUπ 0 UUπ 0 UUπ 0 UUπ0UUπ0UUπ 0 UUπ 0] UUπ0UUπ0UUπ0UUπ 0] UUπ0UUπ0UUπ 0] UUπ0UUπ0UUπ0UUπ0UUπ 0] UUπ0UUπ 0] UUπ0UUπ0UUπ 0 UUπ 0 UUπ 0 UUπ0UUπ 00UUπ 0 UUπ 0 UUπ 0 UUπ 0 UUπ 0 UUπ 0 UUπ0UUπ0UUπ 0 UUπ 0UUπ 0UUπ 0UUπ 0UUπ 0UUπ 0UUπ0UUπ 00UUπ 0:UUπ 0:UUπ0UUπ0UUπ0UUπ 0:UUπ 0:UUπ 0:UUπ 0:UUπ 0:UUπ0UUπ 0UUπ 0UUπ 0UUπ 0UUπ0UUπ0UUπ 00π 0إπ 0إπ 0إπ 0إπ 0إπ 0إπ0إπ0إπH 0إπH 0إπ 0π 0π 0π 0π 0π0π0π 0π 0π0π0π0π0π 0π 0π 0π 0π 0π 0π0π0π 0π0π 0π0π 0π 0π 0kπ 0kπ 0kπ 0kπ 0kπ 0π 0π 0π 0π 0π0π0π0π 0π 0π 0AAAπ 0AAAπ 0AAAπ 0AAAπ 0AAπ 0AAπ 0AAπ 0AAπ 0AAπ 0AAπ 0AAπ 0AAπ0AAπ0AAπ0AAπ0AAπ 0AAπ 0AAπ 0AAπ0AAπ0AAπ 0AAπ 0AAπ 0AAπ 0AAπ 0]!AAπ 0AAπ 0!AAπ 0!AAπ 0!AAπ 0AAπ 0"AAπ 0"AAπ0AAπ0AAπ 0AAπ 0$#AAπ 0$#AAπ 0$#AAπ 0$#AAπ0AAπ0AAϠ@0AAϠ@0AAϠ@0AAπ@0AAπ@0AAπ0AAπ@0AAϠ0AAπ0AAπ0AAπ0AAπ0AAπ0AAπ@0AAϠ@0AAϠ0AAπ 0$#AAπ 0 &AAπ 0 &AAπ 0 &AAπ 0 &AAπ 0 &AAπ0AAπ0AAπ0AAπ 0π05'%π05'%π05'%π05'%π05'%π05'%π05'%π05'%π05'%π05'%π 05'%π05'%π05'%π 05'؁&π05'%π 05'%π05'%π 05'%π05'%π05'%π 05'%π0=@0=@0=@0N 2#( AF#%*,4-12!"$%&')*+,-./2 +j+l+n+++,CtC !!UYEHISUY`d0 7 x ~ 1 7 M U W ]   , 5 < C e p w {  " %'/17(grY]`i4?AHJQSZ\fhqRZIO}.2~ en !$!0!G!S!["d""""""#$#?#A#N#####$&$}$$$$I&R&x&&&&&&&&&&&'((((((t,,:F NR#~DF, 5 e p RWendk''Q'\'<(=(t,,:::::::::::::::::::::::::::::^~8<~;R(7'T޵3tJ>c"9d9^%.V;:*s?\>}"DJ|&M¬CW첐#oNX8pO.8[؋.Lq]8A2h2hhh^h`.h88^8`.hL^`L.h  ^ `.h  ^ `.hxLx^x`L.hHH^H`.h^`.hL^`L.hh^h`o(.^`.TLT^T`L.$ $ ^$ `.  ^ `.L^`L.^`.dd^d`.4L4^4`L.L^`L. ^`o(hH.^`.^`.^`.^`.,,^,`.^`.L^`L.88^8`o(.^`.L^`L.TT^T`.$ $ ^$ `. L ^ `L.^`.^`.dLd^d`L.^`. ^`hH. pLp^p`LhH. @ @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PLP^P`LhH.T^`.T ^`hH.T pLp^p`LhH.T @ @ ^@ `hH.T ^`hH.T L^`LhH.T ^`hH.T ^`hH.T PLP^P`LhH.h^`.h^`.hpLp^p`L.h@ @ ^@ `.h^`.hL^`L.h^`.h^`.hPLP^P`L.L^`L.^`.^`.^`.^`.^`.,,^,`.^`.L^`L.L^`L. ^`o(hH.^`.^`.^`.^`.,,^,`.^`.L^`L.^`.^`.pLp^p`L.@ @ ^@ `.^`.L^`L.^`.^`.PLP^P`L.L^`L. ^`o(hH.^`.^`.^`.^`.,,^,`OJQJo(hH^`.L^`L.L^`L. ^`o(hH.^`.^`.^`.^`.,,^,`.^`.L^`L.^`. ^`hH. pLp^p`LhH. @ @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PLP^P`LhH. ^`o(hH. ^`hH. pLp^p`LhH. @ @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PLP^P`LhH.hh^h`.^`.L^`L.  ^ `.\ \ ^\ `.,L,^,`L.^`.^`.L^`L.;RCW3tJ;2h&M^~Lq].8[c"as?}"D7'oNX9^%        -4  \'        KLw_$$$$V%& &,@m+m+0m+m+b, @UnknownGTimes New Roman5Symbol3 ArialA Trebuchet MSe& ??Arial Unicode MS0000҉0 Pro W3;Wingdings"phe,&8s$ N !>4d*-&" 3q`$SACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction cscuserDanielle LongoH           Oh+'0$0@ Xd    'TACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction cscuserNormalDanielle Longo3Microsoft Word 11.3@P@|.@@s= s$ ՜.+,D՜.+,` hp  @'(St Vincent's Catholic Medical CentersN*- TACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction Title 8@ _PID_HLINKS'A &8k1  jac1716t03]1 ja09965120t2  !"#$%&'()*+,-./023456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghjklmnopqrstuvwxyz{|}~Root Entry Fl=Data 1un1TableiWordDocument"`SummaryInformation(DocumentSummaryInformation8CompObjXObjectPooll=l= FMicrosoft Word DocumentNB6WWord.Document.8